Simultaneously, angiosarcoma genome analyses revealed mutations and amplifications of VEGF, MDM2, TP53, CDKN2A, KRAS and MYC. TP53 was reported as mutated in 35% of the lesions and CDKN2A lost in 26%. The gene discussed is TP53; the disease is angiosarcoma.